Cue Biopharma, Inc.
CUE
Rank in Stocks
#18040
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on... Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
Share Price
$20.14
Last synced: 2026-11-09
Market Cap
$146.31M
Change (1 day)
7.53%
Change (1 year)
-1.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cue Biopharma, Inc. (CUE)
Category
Healthcare
EPS for Cue Biopharma, Inc. (CUE)
EPS as of June 2026 TTM: $-26.99
According to Cue Biopharma, Inc.'s latest financial reports, its current EPS (TTM) is $-26.99. At the end of 2025 the company had an EPS of $-8.40, an increase over its 2024 EPS of $-21.60.
EPS history for Cue Biopharma, Inc. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-26.99 | 221.31% |
| 2025 | $-8.40 | -61.11% |
| 2024 | $-21.60 | -35.14% |
| 2023 | $-33.30 | -25.50% |
| 2022 | $-44.70 | 5.67% |
| 2021 | $-42.30 | -9.62% |
| 2020 | $-46.80 | -6.02% |
| 2019 | $-49.80 | -14.43% |
| 2018 | $-58.20 | 71.68% |
| 2017 | $-33.90 | 205.41% |
| 2016 | $-11.10 | 42.31% |
| 2015 | $-7.80 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -158.02% |
US
|
|
| $-7.07 | -73.81% |
US
|
|
| $-5.29 | -80.40% |
AU
|
|
| $12.88 | -147.72% |
BE
|
|
| $21.56 | -179.88% |
NL
|
Questions about Cue Biopharma, Inc.'s earnings per share (EPS)
What is Cue Biopharma, Inc.'s earnings per share (EPS)?
Cue Biopharma, Inc.'s earnings per share (EPS) over the last twelve months is $-26.99, as of Jun 2026.
What was Cue Biopharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Cue Biopharma, Inc.'s earnings per share (EPS) was $-8.40, compared with $-21.60 in 2024.
How has Cue Biopharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cue Biopharma, Inc.'s earnings per share (EPS) was highest in 2025 ($-8.40) and lowest in 2020 ($-46.80).
How does Cue Biopharma, Inc.'s earnings per share (EPS) compare with similar companies?
Cue Biopharma, Inc.'s earnings per share (EPS) ($-26.99) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.